Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03294863 · ClinicalTrials.gov registry record · NA
Effectiveness of Embrace Scar Therapy Device After Cutaneous Wound Closure
A NA study, sponsored by University of California, Davis.
- Terminated
- Registry status
- NA
- Development phase
- 49
- Enrollment target
NCT03294863: Clinical Trial NA study, sponsored by University of California, Davis.
NCT03294863 is a NA study that was terminated before completion, run by University of California, Davis. The registered enrollment target is 49 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03294863, a NA study, was terminated before completion, sponsored by University of California, Davis.
- TERMINATED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the use of the embrace device after repair of linear cutaneous surgery wounds improves scar cosmesis.
Primary Outcome
The Patient Observer Scar Assessment Score (POSAS) will be used to compare the cosmetic appearance of scars in the area treated with the device versus the area that was not treated. The POSAS measures scar quality in all types of scars by evaluating visual (e.g. color), tactile (e.g. pliability) and sensory (e.g. itch) characteristics of the scar from the perspective of the observer and patients. Scores for each subscale range from 1 to 10, for a sum score range from 6 to 60. Low scores indicate
Interventions
- OTHER Standard of Care
- DEVICE Embrace Scar Therapy Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2017-03-15 |
| Est. Completion | 2025-12-08 |
| Phase | NA |
Why NCT03294863 stopped before completion
NCT03294863 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT03294863 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03294863 about?
NCT03294863 is a clinical study titled "Effectiveness of Embrace Scar Therapy Device After Cutaneous Wound Closure". The purpose of this study is to determine whether the use of the embrace device after repair of linear cutaneous surgery wounds improves scar cosmesis.
What is the current status of trial NCT03294863?
This trial is currently terminated. It is a NA study. The enrollment target is 49 participants. The study started on 2017-03-15. Estimated completion is 2025-12-08.
What interventions are being tested in trial NCT03294863?
The interventions under investigation include: Standard of Care (OTHER), Embrace Scar Therapy Device (DEVICE).
Who is sponsoring clinical trial NCT03294863?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03294863's enrollment target sits among peer trials
49 1379th of 2000 higher than 620 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI